CellCentric Makes Two Appointments
This article was originally published in Scrip
Executive Summary
CellCentric, a company developing anti-cancer compounds, has appointed Nigel Brooks director of translational science and Martin Page consultant. Brooks was previously involved in AstraZeneca Plc's clinical trials and he also led the AstraZeneca urology disease area team. He currently holds a senior leadership role at the Manchester Cancer Research Centre. Page brings experience in oncology R&D and held various senior management positions including European oncology therapeutic area head for Glaxo-Wellcome, and global head of oncology research for Johnson & Johnson Pharmaceuticals where he was vice president.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.